The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies

Nathan M Radcliffe
Ophthalmology, New York University, New York, NY, USA

Abstract: Glaucomatous optic atrophy is the second most common cause of blindness worldwide, and lowering intraocular pressure (IOP) is the only proven method to slow or stop the progression of the disease. Approximately 40% of patients with elevated IOP will require more than one medication to obtain a modest 20% reduction in IOP, and as a result, some patients may require two medications, provided in either two separate bottles or in one bottle with the use of fixed-combination therapies. Each therapy has its own unique safety and efficacy profile. Topical beta-blockers have a particularly favorable ocular-tolerability profile, and several studies of fixed-combination medications containing the beta-blocker timolol maleate have shown a lower prevalence of some ocular adverse events for the fixed-combination therapy compared to the non-beta-blocker individual component. In this review, we examined clinical data pertaining to the ocular surface tolerability of fixed-combination medications containing timolol maleate in comparison to the individual components. In particular, preference was given to prospective, randomized, multicenter trials of 3 months in duration or longer that compared a fixed-combination therapy to monotherapy with the individual components. A review of the literature revealed that some fixed-combination therapies can provide a reduced risk of common side effects compared to their individual components, with conjunctival hyperemia and ocular allergy being less frequent in some timolol-containing fixed-combination therapies. This effect appears to be most significant for latanoprost 0.005%, bimatoprost 0.03%, and brimonidine 0.2%.

Keywords: bimatoprost, brimonidine, hyperemia, latanoprost, ocular allergy

Introduction
Glucomatous optic atrophy is the second most common cause of blindness worldwide and its prevalence increases with certain risk factors, including older age and elevated intraocular pressure (IOP). Lowering IOP is the only proven method to slow or stop the progression of the disease. While incisional and laser-based glaucoma therapies have been shown to effectively treat glaucoma, topical ocular hypotensive therapy is the current mainstay of treatment. Commonly used classes of ocular hypotensive medications include prostaglandin analogs (including prostamides), beta-adrenergic antagonists (beta-blockers), alpha-adrenergic agonists, and carbonic anhydrase inhibitors. Each of the available molecules from these classes of medications possesses its own unique profile in terms of efficacy, duration of action, dosing requirements, and ocular and systemic tolerability.

Approximately 40% of patients with elevated IOP will be unable to achieve a modest 20% reduction in IOP with the use of a single medication. As a result, patients...
may require more than one medication, provided in either two separate bottles or in one bottle with the use of fixed-combination therapies.

Single-bottle therapies have inherent advantages over two-bottle therapies. Studies of pharmacy-claims data have demonstrated that patients receiving two IOP-lowering medications with fixed-combination eye drops are more likely to adhere to a year of therapy than those receiving two medications in two separate bottles. Additionally, taking multiple medications in two separate bottles compared to a fixed-combination typically increases exposure to preservatives, increases the complexity and time commitments of the medical regimen, and can potentially allow the first medication to be “washed out” by the application of the second.

Currently, the majority of available fixed-combination therapies contain a beta-blocker (usually timolol maleate) in addition to another IOP-lowering agent. While it might be expected that the combination of two medications would result in a safety profile that represents the sum of adverse events experienced with the individual components, several studies of fixed-combination medications containing the beta-blocker timolol maleate have shown a reduction of some ocular adverse events compared to the non-beta-blocker individual component. In this review, we will examine clinical data pertaining to the ocular surface tolerability of fixed-combination medications containing timolol maleate in comparison to the individual components.

**Beta-adrenergic antagonists**

Beta-blockers lower IOP by inhibiting aqueous humor production from the nonpigmented ciliary body epithelium through antagonism of β-1 and β-2 receptors. The beta-blocker class has been commercially available for the treatment of glaucoma since initial U.S. Food and Drug Administration (FDA) approval in 1978 and represents one of the most frequently prescribed topical treatments for glaucoma. Advantages of beta-blocker glaucoma therapies include the possibility for daily dosing, including well-established efficacy and a favorable ocular tolerability profile. Several beta-blocker molecules have been developed for ophthalmic use, including timolol maleate, carteolol, levobunolol, metipranolol, and betaxolol. In the Ocular Hypertension Treatment Study, 817 subjects randomized to timolol maleate 0.5% twice daily experienced a 5.9±3.4 mmHg (22%±12%) reduction in IOP. Beta-blockers are contraindicated or must be used with careful consideration and caution in patients with bradycardia, heart failure, bronchospasm, asthma, and other obstructive pulmonary diseases. Ocular adverse events with timolol are typically mild and include allergy, stinging or burning upon application, and blurred vision. In one 12-month prospective study reported by Sherwood et al, 392 patients using timolol maleate 0.5% twice daily for 12 months were studied carefully for adverse events, and the most common cumulative adverse event (occurring in >5% of patients) was conjunctival allergy (12%), followed by conjunctival hyperemia (7.4%) and ocular stinging (6.6%). Because of its efficacy and tolerability profile, timolol maleate has maintained an important role in the treatment of glaucoma.

**Fixed combinations including timolol and a prostaglandin analog**

The prostaglandin analog class of medications has replaced beta-blockers as the preferred agent for primary glaucoma treatment. Favorable attributes of the prostaglandin analog class include excellent IOP-lowering efficacy, 24-hour IOP control with once-daily dosing, and an acceptable topical side effect profile with very minimal systemic effects. The prostaglandin analog class of medications reduces IOP by increasing aqueous egress through the uveoscleral outflow pathway. Bimatoprost is classified as a prostamide, is not a prodrug like the prostaglandin analogs, and may function differently than other members of the prostaglandin analog class; however, for the purposes of this review, we consider all agents to be prostaglandin analogs.

In one prospective study comparing the three most widely-used prostaglandin analogs, 410 patients were randomized evenly to three prostaglandin analogs and were followed for 12 weeks. In terms of IOP lowering, treatment produced mean IOP reductions of 6.7±3.2 mmHg for travoprost, 7.0±3.2 mmHg for latanoprost 0.005%, and 7.3±3.1 mmHg for bimatoprost 0.03%. Hyperemia rates were 34.8% for bimatoprost 0.03%, 27.3% for travoprost 0.004%, and 16% for latanoprost 0.005%. Hyperemia is the most commonly reported adverse event of the prostaglandin analogs and in some studies has occurred in up to 48% of treated patients, impacting patient persistence with glaucoma therapy. Because hyperemia may interfere with the use of prostaglandin analogs, efforts have been made to reformulate some prostaglandin analogs in order to improve tolerability.

The combination of timolol with a prostaglandin analog is an appealing fixed-combination therapy for several reasons. Added to a prostaglandin analog, timolol has been considered to be a sensible option and, additionally, has been the most popular adjunctive treatment with a prostaglandin analog. Both agents may be dosed daily, have well-established efficacy as monotherapy, and have acceptable tolerability.
profiles. Additionally, the two agents utilize complementary mechanisms of action that represent the two most successful approaches to lowering IOP: the reduction of aqueous humor production and the augmentation of aqueous outflow through the uveoscleral pathway. Finally, several long-term prospective studies have demonstrated that, together, their efficacy is additive.\textsuperscript{20}

**Fixed combination latanoprost 0.005% and timolol maleate 0.5%**

Higginbotham et al reported on outcomes of the first available fixed combination containing a prostaglandin analog and a beta-blocker: fixed combination latanoprost 0.005% and timolol maleate 0.5%.\textsuperscript{19} Patients with open-angle glaucoma or ocular hypertension were randomized into three parallel treatment groups receiving the fixed combination or either of the active controls, with daily dosage in the latanoprost 0.005% and fixed combination arm and twice-daily dosage in the timolol arm. The main outcome measure was IOP reduction at 6 months. After 6 months, all 332 patients in the study were switched to an open-label extension phase using the fixed combination only. Across the three groups, eye irritation was the most commonly reported adverse event and occurred in 15/140 (10.7%) patients randomized to latanoprost 0.005%, 12/140 (8.6%) patients randomized to timolol maleate 0.5%, and 19/138 (13.8%) patients randomized to the fixed combination. Conjunctival hyperemia occurred in 18 (12.9%) patients on latanoprost 0.005% therapy, two (1.4%) patients on timolol 0.5%, and nine (6.5%) patients using the fixed-combination therapy. While the investigators did not report a statistical comparison of the differences in adverse events between groups, by 6 months, twice as many patients developed hyperemia while receiving latanoprost 0.005% compared to the fixed combination. In summary, the single long-term study to compare latanoprost 0.005% to its fixed combination containing timolol maleate 0.5% demonstrated a lower incidence of conjunctival hyperemia using the fixed-combination therapy.

**Fixed-combination bimatoprost 0.03% and timolol 0.5%**

Brandt et al reported outcomes from two identical 3-month prospective double-masked, parallel-design, randomized controlled trials performed at almost 60 study sites.\textsuperscript{22} In a 2:1:1 design, patients were randomized to fixed-combination bimatoprost 0.03% and timolol 0.5% dosed once daily in the morning; bimatoprost 0.03% dosed once daily in the evening; or timolol 0.5% dosed twice daily. In both studies, 987 patients were evaluated for safety at 3 months. The overall safety profile differed significantly between the three groups, with treatment-related adverse events being reported in 41.5% of the fixed-combination group, 50.9% of the bimatoprost 0.03% monotherapy group, and 24.7% of the timolol maleate 0.5% group ($P<0.001$). Conjunctival hyperemia was the most commonly reported adverse event, occurring in 38.5% of patients randomized to bimatoprost 0.03%, 22.7% of patients randomized to the fixed combination, and 6.8% of patients randomized to timolol 0.5% ($P<0.001$). Eye pruritus was lowest in the timolol group at 0.8%, followed by the fixed-combination group at 5.1%, and finally the bimatoprost 0.03% group at 8.7% ($P<0.001$). Not all adverse events were lower in the fixed-combination group compared to bimatoprost 0.03%; for example, eyelash growth occurred in 3.6% and 3.8% of patients on the fixed combination and bimatoprost 0.03%, respectively, but in only 0.4% of patients on timolol 0.5% ($P=0.022$). Stinging sensation differed significantly between groups ($P=0.046$) and was most common in the timolol group (3.4%), followed by the fixed-combination group (2.4%) and then by the bimatoprost group (0.4%).

Lewis et al reported the 12-month outcomes from the Brandt et al study\textsuperscript{22} comparing bimatoprost 0.03% and timolol 0.5% to its individual components.\textsuperscript{23} The findings at 3 months were essentially preserved, with conjunctival hyperemia being the most common adverse event occurring in 25.7% of patients receiving the fixed combination, 43.4% of patients receiving bimatoprost 0.03%, and 8.7% of patients receiving timolol ($P<0.001$). Burning sensation was more common in the timolol 0.5% (10.3%) and fixed-combination (8.3%) groups than the bimatoprost 0.03% arm (10.3%; $P=0.043$), with a similar finding for stinging sensation. Eyelash growth occurred more frequently and at similar rates, both in arms containing bimatoprost 0.03%, but eyelid pigmentation occurred less frequently in the fixed-combination group (3.2%) than in the bimatoprost arm (9.1%; $P<0.001$). Taken together, these findings suggest that timolol maleate, when given in a fixed combination with bimatoprost 0.03%, can be associated with a lower incidence of some, but perhaps not all, of the ocular adverse events associated with bimatoprost. After 1 year, these differences in tolerability did seem to be clinically significant, as 4.2% of patients in the study discontinued participation due to conjunctival hyperemia in the bimatoprost 0.03% group, but only 1.5% in the fixed-combination group and 1.9% in the timolol 0.5% group ($P<0.044$).
Konstas et al evaluated 60 patients with exfoliation glaucoma in a prospective, investigator-masked, crossover comparison of bimatoprost 0.03% and timolol 0.5% compared to bimatoprost 0.03% monotherapy. The investigators found that conjunctival hyperemia occurred in 25% of patients receiving bimatoprost 0.03% compared to only 6.7% of patients receiving the fixed combination (P = 0.03%). However, stinging was more common, occurring in 25% of eyes receiving the fixed combination as compared to 10% of eyes receiving bimatoprost 0.03% (P = 0.022). Katsanos et al performed a small (n = 33) single-arm study in which patients were run in on bimatoprost for 5 weeks and then switched to bimatoprost 0.03% and timolol 0.5% fixed combination. Ocular hyperemia was present in seven patients (21.2%) receiving bimatoprost monotherapy and in only two (6%) after the switch to the fixed combination (P = 0.06). There was a total of 29 adverse ocular events with bimatoprost 0.03% compared to 19 with the fixed combination (P = 0.09).

Paranhos et al sought to evaluate changes in hyperemia and IOP in patients who were switched from prostaglandin analog monotherapy to a fixed combination of bimatoprost 0.03% and timolol 0.5%. In this multicenter longitudinal, noncontrolled, nonrandomized, open-label trial study of 282 eyes of 144 patients, IOP and conjunctival hyperemia were assessed prior to treatment with the fixed combination and 4 months after the medication was switched. Four months after a switch to the beta-blocker containing fixed combination, hyperemia was reduced in patients who had previously used travoprost 0.004%, latanoprost 0.005%, or bimatoprost 0.03%. Graded on a scale from 0 to 3, hyperemia was reduced more than 50% after switching from the bimatoprost 0.03% and travoprost 0.004% monotherapy groups, and less so in the latanoprost 0.005% group, which also had a lower level of baseline hyperemia. All groups experienced significant IOP reduction with the fixed-combination therapy.

In summary, there is strong evidence from several large prospective longitudinal trials that hyperemia seen with bimatoprost 0.03% is reduced when that agent is taken in a fixed-combination therapy with timolol maleate 0.5%.

**Fixed-combination travoprost and timolol**

Barnebey et al reported the results of a 3-month prospective, randomized, multicenter, double-masked, active-controlled, parallel-group study comparing travoprost 0.004% alone to a fixed combination of travoprost 0.004%/timolol maleate 0.5% in patients with ocular hypertension or open-angle glaucoma. All therapies in this study contained benzalkonium chloride as the preservative. Ocular hyperemia was assessed at all IOP time points (8 am, 10 am, and 4 pm) and a slit-lamp examination was performed at 8 am at each visit. The primary outcome of the study was mean IOP; however, each of the 263 patients enrolled in the study was evaluated for safety. Patient-reported ocular hyperemia occurred in 14% of patients receiving the fixed combination and in 12% of patients receiving travoprost 0.004%. Seven percent of patients receiving timolol 0.5% reported ocular discomfort, and only one patient, or 1.1%, in the timolol group reported hyperemia. No additional systemic or topical safety concerns were reported. Therefore, in this 3-month study, there was no observed difference in ocular tolerability between the fixed combination and travoprost 0.004%. Although the study carefully assessed ocular adverse events, it is possible that the study was underpowered to find a small benefit in terms of tolerability, although the study was likely large enough to detect any clinically relevant tolerability differences. It is also possible that hyperemia associated with travoprost is of a different nature than hyperemia seen with latanoprost and bimatoprost.

**Summary of fixed-combination prostaglandin analogs and timolol maleate**

Quaranta et al performed a meta-analysis of 18 prospective randomized trials comparing fixed combinations of prostaglandin analogs and timolol to prostaglandin monotherapy or to the two medications taken as an unfixed combination in separate bottles. Compared to monotherapy with a prostaglandin analog, the fixed-combination therapies were associated with significantly lower hyperemia risk ratio (RR) of 0.61 (95% confidence interval [CI]: 0.53–0.70). Consistent with findings reviewed above, the amount of hyperemia reduction in the fixed combination depended on the prostaglandin molecule received prior to the switch. Bimatoprost 0.03% demonstrated the largest magnitude of hyperemia reduction (RR: 0.59, 95% CI: 0.51–0.68) followed by latanoprost 0.005% (RR: 0.65, 95% CI: 0.42–0.99). The reduction in hyperemia from travoprost was not statistically significant (RR: 0.94, 95% CI: 0.50–1.77); however, there were the fewest studies in the travoprost group and the CIs for that group were the widest, demonstrating that there is some uncertainty regarding the magnitude and direction of the effect.
The above findings support that hyperemia reduction occurs from the addition of timolol maleate in fixed combination with a prostaglandin analog, particularly if that prostaglandin analog is bimatoprost 0.03% or latanoprost 0.005%. The mechanism of how a beta-blocker might alleviate prostaglandin-induced hyperemia is unknown. Several hypotheses exist, but the exact cause of prostaglandin-mediated hyperemia is also incompletely understood. Hyperemia associated with prostaglandin analog use is not considered to be inflammatory in nature, as inflammation was not observed on histological evaluation of conjunctival biopsies. It has been suggested that intracellular calcium and endothelium-derived nitric oxide cause conjunctival vasodilation and hyperemia from prostaglandin analogs. Beta-blockers may inhibit nitric oxide production induced by endogenous catecholamines that are involved with conjunctival hyperemia.

**Ocular tolerability of carbonic anhydrase inhibitors in combination with timolol maleate**

The carbonic anhydrase inhibitor class has been used in humans for glaucoma treatment since 1954 when Becker reported its efficacy for the reduction of IOP as an oral agent. Of the fixed combinations currently available in the United States, dorzolamide hydrochloride 2% and timolol maleate 0.5% fixed combination has been available the longest, having achieved FDA approval in 1998. Today, two topical carbonic anhydrase inhibitors, dorzolamide and brinzolamide, have been formulated for glaucoma therapy and are available in fixed combination with timolol maleate; however, only dorzolamide timolol fixed combination is FDA-approved and has been studied in comparison with its individual components. In a prospective, randomized study evaluating differences in ocular discomfort between two fixed combinations containing the preservative benzalkonium chloride, the fixed combination containing dorzolamide and timolol was associated with greater ocular discomfort than the fixed combination of brinzolamide and timolol.

Boyle performed a 3-month, parallel-design, randomized, double-masked, active-controlled, multicenter clinical trial, randomizing 335 patients to timolol maleate 0.5%, dorzolamide 2%, or the fixed combination. The study demonstrated an IOP-lowering benefit of the fixed combination compared to the individual components. Discontinuations due to adverse events occurred in 7% of patients using the fixed combination and in 1% of patients using timolol maleate 0.5%. The most commonly reported adverse events included blurred vision, burning, stinging, and tearing, and occurred in more patients using the fixed combination compared to timolol. Hyperemia occurred in 1% of patients using timolol 0.5%, in 4% using dorzolamide, and in 3% of patients using the fixed combination.

Clineschmidt et al performed a similar prospective, randomized, clinical trial comparing timolol maleate 0.5%, dorzolamide 2%, and the fixed combination. The study included 253 patients and evaluated efficacy and tolerability at 3 months. As with the Boyle study, patients randomized to timolol had fewer adverse events than those using either dorzolamide 2% or the fixed combination, which had similar safety profiles. Burning and stinging were the most common local adverse events and occurred in 45% of patients using the combination, 45% of patients using dorzolamide, and 27% of those using timolol. Dorzolamide-containing fixed combinations may provide nighttime IOP control. In a prospective, randomized 3-month study comparing 24-hour IOP reduction in patients receiving either dorzolamide–timolol or brimonidine–timolol, dorzolamide–timolol reduced 24-hour IOP by 0.7 mmHg more than brimonidine–timolol (P=0.001), although both medications significantly reduced IOP (P=0.001). The mechanism for this difference has not been elucidated, and the relative importance of nighttime IOP control remains unclear, as all prospective National Institute of Health-sponsored studies have only included daytime IOP.

In summary, the addition of timolol to dorzolamide in a fixed combination did not appear to significantly reduce the ocular tolerability in comparison to dorzolamide alone, although timolol was better tolerated than either dorzolamide or the fixed combination in both studies. While both studies contained several hundred patients and evaluated the individual components in comparison to the combination, the studies were only 3 months in duration, so it is possible, though perhaps unlikely, that an effect could have emerged if given more time. Additionally, it is notable that stinging and burning, not hyperemia, were the most common side effects with both dorzolamide and the fixed combination. Because timolol itself is associated with stinging, and because dorzolamide causes stinging but has a low rate of hyperemia, the addition of timolol was unable to benefit the tolerability profile of fixed-combination dorzolamide 2% and timolol maleate 0.5%.

**Ocular tolerability of alpha-adrenergic agonists in combination with beta-blockers**

The alpha-adrenergic class has been used as an ocular hypotensive agent since apraclonidine was first FDA-approved
for topical ophthalmic use in 1989. Apraclonidine is a para-amin derivative of clonidine with relative alpha-adrenergic selectivity and was initially used to blunt argon laser trabeculoplasty-related IOP elevations. However, the 1% concentration of apraclonidine, formulated for chronic glaucoma treatment, was found to have a 48% incidence of severe follicular conjunctivitis resulting in discontinuation after a mean duration of 13.3 months.

Brimonidine is an alpha-agonist initially introduced in a 0.5% concentration for prophylaxis of IOP elevations following laser trabeculectomy. Brimonidine 0.5% can reduce IOP significantly in the short-term. For example, with brimonidine 0.5%, the incidence of IOP elevation >5 mmHg after argon laser trabeculoplasty was 38% whereas with brimonidine 0.5%, these pressure elevations occurred in only 3%–9% of cases. Brimonidine has subsequently been reformulated into 0.2%, 0.15%, and 0.1% concentrations with accompanying changes in pH, preservative, viscosity, and electrolyte formulation. In the 0.2% concentration taken three times daily, brimonidine has been shown to reduce IOP by roughly 20% from baseline and has a 12-month allergic conjunctivitis rate of 9.4%. Researchers have demonstrated that brimonidine likely utilizes both the aqueous suppression as well as uveoscleral outflow pathways. Because of its complementary mechanisms of action, potential for twice-daily dosing in a fixed combination, and favorable efficacy and safety profile, a brimonidine 0.2% and timolol 0.5% fixed combination was developed by Allergan, Inc. (Irvine, CA, USA), receiving approval by the FDA in 2007.

Sherwood et al reported 12-month outcomes on the safety and efficacy of twice-daily brimonidine 0.2% and timolol 0.5% fixed combination compared to monotherapy with either twice-daily timolol 0.5% or three-times-daily brimonidine 0.2% in two identical randomized double-masked multicenter trials. In this investigation, patients receiving the fixed combination had a lower incidence of treatment-related adverse events. Adverse events occurred in 62.8% of the brimonidine 0.2% monotherapy group compared to 53.0% in the fixed-combination group (P=0.006) with similar differences in discontinuations due to adverse events (30.6% with brimonidine monotherapy and 14.3% with the fixed combination, P<0.001). Those adverse events related to allergic conjunctivitis occurred in 39.8% of patients receiving brimonidine compared to 26.0% of patients receiving the fixed combination (P<0.001). Conjunctival hyperemia was lowest with timolol (7.4%), followed by the fixed combination (14.8%), and was highest with brimonidine (22.8%; P=0.001–0.003). As has been seen in previous studies, both timolol and the fixed combination had a higher rate of stinging (6.6% and 6.2%, respectively) than brimonidine (2.9%, P=0.03 compared to the fixed combinations). Note that brimonidine was dosed three times daily, consistent with its FDA approval and a necessary design feature in order to meet regulatory requirements, which may account for the higher occurrence of adverse outcomes in the brimonidine arm.

Motolko performed a comparative, nonrandomized, single-site, interventional study in which patients receiving fixed combination of brimonidine 0.2% and timolol 0.5% were compared to those receiving brimonidine 0.2% twice daily as monotherapy. Ocular allergy in the 204 patients evaluated in this study was defined as the presence of conjunctival follicles significant enough to result in discontinuation of the medication. Over 18 months, allergic conjunctivitis occurred in 17.6% of the brimonidine twice-daily group and 8.8% of the fixed-combination group (P=0.09). While the finding was not statistically significant, the incidence of ocular allergy was 50% lower in the fixed-combination group. The Kaplan–Meier survival analysis evaluating whether ocular allergy may be delayed or reduced in the fixed-combination group suggested a statistical trend for a protective effect from the fixed combination (P=0.066). Therefore, in this investigation of twice-daily brimonidine 0.2% compared to the fixed combination of timolol and brimonidine, the fixed combination demonstrated similar tolerability advantages as seen when the fixed combination was compared to three-times-daily brimonidine.

Osborne et al investigated brimonidine allergy by evaluating a database of 463 patients treated for elevated IOP with pharmacotherapy. The authors noted that allergy to timolol presented more quickly in patients who had previously demonstrated an allergy to timolol, but that those who used timolol initially had a longer period of time until the development of brimonidine allergy (P=0.037). The authors concluded that brimonidine allergy can induce allergy to timolol, but that prior use of timolol might suppress the subsequent development of brimonidine allergy.

Butler et al hypothesized that adrenergic agents may induce allergic response by reducing conjunctival cell volume, which would induce a widening of intercellular spaces, increasing the likelihood that allergens could reach subepithelial tissue. Evidence in support of this theory comes from a study by Alvarado et al in cultured human trabecular meshwork and Schlemm’s canal endothelial cells, which demonstrated decreased cell volume after exposure to adrenergic agonists. Theoretically, a beta-adrenergic antagonist could inhibit the decrease in cell volume caused by an alpha-adrenergic agent, which would inhibit allergic
exposure and subsequent allergy development. In summary, there is good evidence from several prospective studies that brimonidine ocular surface tolerability is improved by the presence of timolol in fixed-combination therapy, and that this benefit applies to both hyperemia and the characteristic brimonidine allergy.

Discussion

Timolol maleate appears to provide benefits to the ocular surface in fixed combinations containing some prostaglandin analogs and alpha-agonists (Table 1). Beta-blockers seem to limit hyperemia, possibly by interfering with pharmacologic mediators of hyperemia, and may decrease allergy by inhibiting intracellular volume reduction. However, some important questions remain. If timolol is protective against ocular surface adverse events, is it necessary for the timolol to be contained in a fixed combination, or can the protection be achieved with concomitant therapy in a separate bottle? While Osborne et al’s study suggested that protection against brimonidine allergy could be achieved by timolol use in a separate bottle, other data suggest that the benefit may be greatest when timolol is contained within a fixed combination. Schuman et al performed a prospective, randomized, double-masked, parallel-group, multicenter trial comparing travoprost 0.004%/timolol 0.5% to concomitant timolol 0.5% and travoprost 0.004% daily or to timolol 0.5% twice daily and found that tolerability can differ between concomitant therapy and fixed-combination therapy. Conjunctival hyperemia occurred in 14.3% of patients receiving the fixed combination (taken in the morning) compared to 23.4% of subjects receiving concomitant therapy (with the prostaglandin analog dosed in the evening and timolol dosed in the morning). This study suggests that the benefits of timolol on ocular tolerability may be greater when the timolol is in the same bottle as the prostaglandin analog, although an alternative explanation is that the two agents were also dosed at the same time in the fixed combination whereas concomitant therapy was dosed at opposite times of the day. In a similar large study comparing fixed-combination timolol 0.5% and travoprost 0.004% to travoprost 0.004% and timolol 0.5% taken in separate bottles and dosed at the same time of day, the ocular tolerability of fixed-combination travoprost 0.004%/timolol 0.5% was similar to concomitant therapy, with hyperemia occurring in 12.4% of those receiving the fixed-combination and 13.5% of those receiving concomitant therapy.

Hommer et al randomized 445 patients to therapy with fixed-combination bimatoprost 0.03%/timolol 0.5% taken daily; concomitant therapy with daily bimatoprost 0.03% and twice-daily timolol 0.5%; or daily bimatoprost 0.03% (which was a smaller portion of the study patients). Interestingly, the cumulative prevalence of conjunctival hyperemia was slightly lower (but not statistically so; \( P=0.218 \)) in the fixed-combination group (19.3%) compared with the non-concomitant-therapy group (25.6%) and the bimatoprost monotherapy group (27.8%). Based on conjunctival hyperemia graded during slit-lamp examination, the incidence of hyperemia increase by one or more grades was higher in the bimatoprost group (18.9%) than in the fixed-combination group (8.5%, \( P=0.014 \)), with the concomitant-therapy group falling in between the two at 12.5% (not statistically significant). The incidence of ocular burning was higher in the concomitant-therapy group (14.2%) than in the fixed-combination (6.8%, \( P=0.024 \)) and bimatoprost groups (5.6%, \( P=0.035 \). In summary, there is some conflicting data demonstrating the benefits of timolol on the ocular surface in patients receiving concomitant therapy, though several investigations suggest that timolol’s greatest benefit may be achieved when in a fixed combination rather than when taken as concomitant therapy.

Table 1

<table>
<thead>
<tr>
<th>Authors</th>
<th>Component</th>
<th>N</th>
<th>Duration (months)</th>
<th>Hyperemia incidence</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Higginbotham et al (^{21})</td>
<td>Latanoprost 0.005%</td>
<td>332</td>
<td>6</td>
<td>1.4%</td>
<td>12.9%</td>
</tr>
<tr>
<td>Brandt et al (^{22})</td>
<td>Bimatoprost 0.03%</td>
<td>987</td>
<td>3</td>
<td>6.8%</td>
<td>38.5%</td>
</tr>
<tr>
<td>Lewis et al (^{23})</td>
<td>Bimatoprost 0.03%</td>
<td>1061</td>
<td>12</td>
<td>8.7%</td>
<td>43.4%</td>
</tr>
<tr>
<td>Barnebey et al (^{27})</td>
<td>Travoprost 0.004%</td>
<td>263</td>
<td>3</td>
<td>1.1%</td>
<td>14.1%</td>
</tr>
<tr>
<td>Sherwood et al (^{11})</td>
<td>Brimonidine</td>
<td>392</td>
<td>12</td>
<td>0.3%</td>
<td>22.8%</td>
</tr>
<tr>
<td>Boyle et al (^{24})</td>
<td>Dorzolamide</td>
<td>335</td>
<td>3</td>
<td>1%</td>
<td>4%</td>
</tr>
</tbody>
</table>

Abbreviation: ns, nonsignificant.

Conclusion

Fixed-combination therapies offer several advantages to patients with glaucoma, including convenience, reduced exposure to preservatives, reduced risk of medication
washout, ease of compliance, and decreased time requirements for eye drop application. All FDA-approved fixed-combinations have demonstrated added efficacy in comparison to the individual components. However, some fixed-combination therapies can also provide a reduced risk of common side effects compared to their individual components. Conjunctival hyperemia and allergy are two of the most common eye drop side effects and are common causes of medication discontinuation. In this review, we have presented evidence that some fixed-combination therapies that contain timolol maleate have more favorable ocular surface tolerability than the non-timolol individual component. This effect appears to be most significant for latanoprost 0.005%, bimatoprost 0.03%, and brimonidine 0.2%. The effect appears not to be present for dorzolamide, possibly because both timolol and dorzolamide are associated with some stinging, and because dorzolamide and timolol both have lower rates of allergy and hyperemia.

Acknowledgments
This work was supported by Allergan, Inc., the Seth Sprague Educational & Charitable Foundation, and Research to Prevent Blindness.

Disclosures
The author reports the following financial relationships: Reichert (instrument support), Allergan, Inc. (consultant and speaker), Alcon Laboratories (consultant and speaker), Iridex (consultant and speaker), Glauco (consultant and speaker), Merge Healthcare (consultant and speaker), Carl Zeiss Meditec (consultant and speaker). The author reports no other conflicts of interest in this work.

References


42. Motolko MA. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. *Curr Med Res Opin.* 2008;24(9):2663–2667.


46. Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. *J Glaucoma.* 2005;14(5):392–399.